Mozz's scientific paragraph of the year..., page-18

Certainly not disagreeing, but even without an MPS deal, we will have 12 month duration data by Oct/Nov 2023. I sense our share price will be far from the gutter around this time and with 2 neatly packaged programs, being rolled out in the right order…. Ultra rare first, blockbuster OA second, we will have an audience to select partners from. Yes…. An FDA tick would be nice (hopefully accelerated approval) or a commercial licence to sell Zilosul to the MPS community at the least. Perhaps I’m too bullish. But if these dominoes fall in the right order, Coppo will be putting a jet rocket under the share price for 2024. It’s a stab in the dark here. But we can only dream.